Chromocell Therapeutics Files 8-K
Ticker: PTHS · Form: 8-K · Filed: 2024-03-21T00:00:00.000Z
Sentiment: neutral
Topics: 8-K, disclosure, financials
TL;DR
Chromocell Therapeutics filed an 8-K on 3/21/24 covering financial statements and Reg FD disclosures.
AI Summary
Chromocell Therapeutics Corporation filed an 8-K on March 21, 2024, reporting on its current activities. The filing includes information regarding financial statements and exhibits, as well as a Regulation FD Disclosure. The company is incorporated in Delaware and its principal executive office is located in Freehold, NJ.
Why It Matters
This 8-K filing provides an update on Chromocell Therapeutics' regulatory and financial disclosures, which is important for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This filing is a routine disclosure and does not appear to contain any significant new risks or material adverse information.
Key Players & Entities
- Chromocell Therapeutics Corporation (company) — Registrant
- March 21, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Freehold, NJ (location) — Principal Executive Office
FAQ
What is the primary purpose of this 8-K filing for Chromocell Therapeutics?
The primary purpose of this 8-K filing is to report on current events, including financial statements and exhibits, and to provide a Regulation FD Disclosure.
When was this 8-K report filed by Chromocell Therapeutics?
This 8-K report was filed on March 21, 2024.
In which state is Chromocell Therapeutics incorporated?
Chromocell Therapeutics is incorporated in Delaware.
What is the address of Chromocell Therapeutics' principal executive office?
The address of Chromocell Therapeutics' principal executive office is 4400 Route 9 South, Suite 1000, Freehold, NJ 07728.
What is the telephone number for Chromocell Therapeutics' principal executive office?
The telephone number for Chromocell Therapeutics' principal executive office is 732-514-2636.
Filing Stats: 501 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2024-03-21 09:00:52
Key Financial Figures
- $0.0001 — h registered Common Stock, par value $0.0001 per share CHRO The NYSE American LL
Filing Documents
- g084141_8k.htm (8-K) — 32KB
- g084141_ex99-1.htm (EX-99.1) — 12KB
- image_003.jpg (GRAPHIC) — 3KB
- 0001753926-24-000584.txt ( ) — 224KB
- chro-20240321.xsd (EX-101.SCH) — 3KB
- chro-20240321_lab.xml (EX-101.LAB) — 33KB
- chro-20240321_pre.xml (EX-101.PRE) — 22KB
- g084141_8k_htm.xml (XML) — 4KB
01
Item 7.01 Regulation FD Disclosure. On March 21, 2024, the Company issued a press release announcing the launch of its eye pain treatment program with the hiring of Dr. Simon Chandler, a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in such exhibit shall not be deemed filed for purposes of Section 18 of the Securities Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
01
Item 9.01
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of Chromocell Therapeutics Corporation, dated March 21, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 21, 2024 CHROMOCELL THERAPEUTICS CORPORATION By: /s/ Francis Knuettel II Name: Francis Knuettel II Title: Chief Executive Officer and Chief Financial Officer